Changchun High-Tech's subsidiary, Gensci Pharmaceutical, has received approval from the U.S. FDA to commence clinical trials for its GenSci161 injection. This fully human bispecific antibody targets both IL-1α and IL-1β, aiming to improve treatment outcomes for moderate to severe hidradenitis suppurativa. The drug has previously been approved for clinical trials in China for conditions like endometriosis. AI
IMPACT N/A
RANK_REASON Drug clinical trial approval for a specific indication. [lever_c_demoted from research: ic=1 ai=0.1]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
